Abstract
Introduction: Recent studies have suggested a higher incidence of cardiovascular disease (CVD) among patients with chronic kidney disease (CKD) in the USA than in Japan. Hyperphosphatemia, a possible risk for CVD, may explain this difference; however, international differences in phosphate parameters in CKD have not been well elaborated. Methods: By using the baseline data from the USA and the Japanese nation-wide, multicenter, CKD cohort studies; the Chronic Renal Insufficiency Cohort Study (CRIC, N = 3,870) and the Chronic Kidney Disease-Japan Cohort Study (CKD-JAC, N = 2,632), we harmonized the measures and compared clinical parameters regarding phosphate metabolism or serum phosphate, fibroblast growth factor-23 (FGF23), and parathyroid hormone (PTH), in the cross-sectional model. Results: Multivariable linear regression analyses revealed that serum phosphate levels were significantly higher in CRIC across all levels of estimated glomerular filtration rate (eGFR) with the greatest difference being observed at lower levels of eGFR. Serum FGF23 and 25-hydroxy vitamin D (25OHD) levels were higher in CRIC, while PTH levels were higher in CKD-JAC at all levels of eGFR. Adjustments for demographics, 25OHD, medications, dietary intake or urinary excretion of phosphate, PTH, and FGF23 did not eliminate the difference in serum phosphate levels between the cohorts (0.43, 0.46, 0.54, 0.64, and 0.78 mg/dL higher in CRIC within eGFR strata of >50, 41–50, 31–40, 21–30, and ≤20 mL/min/1.73 m2, respectively). These findings were consistent when only Asian CRIC participants (N = 105) were included in the analysis. Conclusion: Serum phosphate levels in CRIC were significantly higher than those of CKD-JAC across all stages of CKD, which may shed light on the international variations in phosphate parameters and thus in cardiovascular risk among CKD patients. The key mechanisms for the substantial differences in phosphate parameters need to be elucidated.
References
1.
Ninomiya
T
, Kiyohara
Y
, Kubo
M
, Tanizaki
Y
, Doi
Y
, Okubo
K
, Chronic kidney disease and cardiovascular disease in a general Japanese population: the Hisayama Study
. Kidney Int
. 2005 Jul
;68
(1
):228
–36
.2.
Irie
F
, Iso
H
, Sairenchi
T
, Fukasawa
N
, Yamagishi
K
, Ikehara
S
, The relationships of proteinuria, serum creatinine, glomerular filtration rate with cardiovascular disease mortality in Japanese general population
. Kidney Int
. 2006 Apr
;69
(7
):1264
–71
.3.
Matsushita
K
, Coresh
J
, Sang
Y
, Chalmers
J
, Fox
C
, Guallar
E
, Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data
. Lancet Diabetes Endocrinol
. 2015 Jul
;3
(7
):514
–25
.4.
Norris
K
, Bourgoigne
J
, Gassman
J
, Hebert
L
, Middleton
J
, Phillips
RA
, Cardiovascular outcomes in the African American Study of Kidney Disease and Hypertension (AASK) Trial
. Am J Kidney Dis
. 2006 Nov
;48
(5
):739
–51
.5.
Rahman
M
, Xie
D
, Feldman
HI
, Go
AS
, He
J
, Kusek
JW
, Association between chronic kidney disease progression and cardiovascular disease: results from the CRIC Study
. Am J Nephrol
. 2014
;40
(5
):399
–407
.6.
Tanaka
K
, Watanabe
T
, Takeuchi
A
, Ohashi
Y
, Nitta
K
, Akizawa
T
, Cardiovascular events and death in Japanese patients with chronic kidney disease
. Kidney Int
. 2017 Jan
;91
(1
):227
–34
.7.
Yoshino
M
, Kuhlmann
MK
, Kotanko
P
, Greenwood
RN
, Pisoni
RL
, Port
FK
, International differences in dialysis mortality reflect background general population atherosclerotic cardiovascular mortality
. J Am Soc Nephrol
. 2006 Dec
;17
(12
):3510
–9
.8.
Tentori
F
, Blayney
MJ
, Albert
JM
, Gillespie
BW
, Kerr
PG
, Bommer
J
, Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS)
. Am J Kidney Dis
. 2008 Sep
;52
(3
):519
–30
.9.
Kestenbaum
B
, Sampson
JN
, Rudser
KD
, Patterson
DJ
, Seliger
SL
, Young
B
, Serum phosphate levels and mortality risk among people with chronic kidney disease
. J Am Soc Nephrol
. 2005 Feb
;16
(2
):520
–8
.10.
Eddington
H
, Hoefield
R
, Sinha
S
, Chrysochou
C
, Lane
B
, Foley
RN
, Serum phosphate and mortality in patients with chronic kidney disease
. Clin J Am Soc Nephrol
. 2010 Dec
;5
(12
):2251
–7
.11.
Tonelli
M
, Sacks
F
, Pfeffer
M
, Gao
Z
, Curhan
G
. Relation between serum phosphate level and cardiovascular event rate in people with coronary disease
. Circulation
. 2005
;112
(17
):2627
–33
. .12.
Adeney
KL
, Siscovick
DS
, Ix
JH
, Seliger
SL
, Shlipak
MG
, Jenny
NS
, Association of serum phosphate with vascular and valvular calcification in moderate CKD
. J Am Soc Nephrol
. 2009 Feb
;20
(2
):381
–7
.13.
Schwarz
S
, Trivedi
BK
, Kalantar-Zadeh
K
, Kovesdy
CP
. Association of disorders in mineral metabolism with progression of chronic kidney disease
. Clin J Am Soc Nephrol
. 2006 Jul
;1
(4
):825
–31
. .14.
Calvo
MS
, Kumar
R
, Heath
H
. Persistently elevated parathyroid hormone secretion and action in young women after four weeks of ingesting high phosphorus, low calcium diets
. J Clin Endocrinol Metab
. 1990 May
;70
(5
):1334
–40
. .15.
Ito
N
, Fukumoto
S
, Takeuchi
Y
, Takeda
S
, Suzuki
H
, Yamashita
T
, Effect of acute changes of serum phosphate on fibroblast growth factor (FGF)23 levels in humans
. J Bone Miner Metab
. 2007
;25
(6
):419
–22
.16.
Nakano
C
, Hamano
T
, Fujii
N
, Matsui
I
, Tomida
K
, Mikami
S
, Combined use of vitamin D status and FGF23 for risk stratification of renal outcome
. Clin J Am Soc Nephrol
. 2012 May
;7
(5
):810
–9
.17.
Feldman
HI
, Appel
LJ
, Chertow
GM
, Cifelli
D
, Cizman
B
, Daugirdas
J
, The Chronic Renal Insufficiency Cohort (CRIC) Study: design and methods
. J Am Soc Nephrol
. 2003 Jul
;14
(7 Suppl 2
):S148
–53
.18.
Lash
JP
, Go
AS
, Appel
LJ
, He
J
, Ojo
A
, Rahman
M
, Chronic Renal Insufficiency Cohort (CRIC) Study: baseline characteristics and associations with kidney function
. Clin J Am Soc Nephrol
. 2009 Aug
;4
(8
):1302
–11
.19.
Fischer
MJ
, Go
AS
, Lora
CM
, Ackerson
L
, Cohan
J
, Kusek
JW
, CKD in Hispanics: baseline characteristics from the CRIC (Chronic Renal Insufficiency Cohort) and Hispanic-CRIC Studies
. Am J Kidney Dis
. 2011 Aug
;58
(2
):214
–27
.20.
Imai
E
, Matsuo
S
, Makino
H
, Watanabe
T
, Akizawa
T
, Nitta
K
, Chronic Kidney Disease Japan Cohort (CKD-JAC) Study: design and methods
. Hypertens Res
. 2008 Jun
;31
(6
):1101
–7
.21.
Imai
E
, Matsuo
S
, Makino
H
, Watanabe
T
, Akizawa
T
, Nitta
K
, Chronic Kidney Disease Japan Cohort Study: baseline characteristics and factors associated with causative diseases and renal function
. Clin Exp Nephrol
. 2010 Dec
;14
(6
):558
–70
.22.
Zhang
R
, Wang
Z
, Fei
Y
, Zhou
B
, Zheng
S
, Wang
L
, The difference in nutrient intakes between Chinese and Mediterranean, Japanese and American diets
. Nutrients
. 2015 Jun
;7
(6
):4661
–88
.23.
Lips
P
. Worldwide status of vitamin D nutrition
. J Steroid Biochem Mol Biol
. 2010 Jul
;121
(1–2
):297
–300
. .24.
Janssen
MJ
, Wielders
JP
, Bekker
CC
, Boesten
LS
, Buijs
MM
, Heijboer
AC
, Multicenter comparison study of current methods to measure 25-hydroxyvitamin D in serum
. Steroids
. 2012 Nov
;77
(13
):1366
–72
.25.
Holmes
EW
, Garbincius
J
, McKenna
KM
. Analytical variability among methods for the measurement of 25-hydroxyvitamin D: still adding to the noise
. Am J Clin Pathol
. 2013 Oct
;140
(4
):550
–60
. .26.
Moore
LW
, Nolte
JV
, Gaber
AO
, Suki
WN
. Association of dietary phosphate and serum phosphorus concentration by levels of kidney function
. Am J Clin Nutr
. 2015 Aug
;102
(2
):444
–53
. .27.
WHO/IASO/IOTF
. The Asia-Pacific perspective: redefining obesity and its treatment
: Health Communications Australia Pty Ltd
; 2000
.28.
World Health Organization
. Obesity: preventing and managing the global endemic
. WHO technical report series
. Geneva
: WHO
; 2000
.29.
Gokce
C
, Gokce
O
, Baydinc
C
, Ilhan
N
, Alasehirli
E
, Ozkucuk
F
, Use of random urine samples to estimate total urinary calcium and phosphate excretion
. Arch Intern Med
. 1991 Aug
;151
(8
):1587
–8
.30.
White
IR
, Royston
P
, Wood
AM
. Multiple imputation using chained equations: issues and guidance for practice
. Stat Med
. 2011 Feb 20
;30
(4
):377
–99
. .31.
Morris
TP
, White
IR
, Royston
P
. Tuning multiple imputation by predictive mean matching and local residual draws
. BMC Med Res Methodol
. 2014
;14
:75
. .32.
National Kidney Foundation
. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease
. Am J Kidney Dis
. 2003 Oct
;42
(4 Suppl 3
):S1
–201
.33.
Levin
A
, Bakris
GL
, Molitch
M
, Smulders
M
, Tian
J
, Williams
LA
, Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease
. Kidney Int
. 2007 Jan
;71
(1
):31
–8
.34.
El-Maouche
D
, Dumitrescu
CE
, Andreopoulou
P
, Gafni
RI
, Brillante
BA
, Bhattacharyya
N
, Stability and degradation of fibroblast growth factor 23 (FGF23): the effect of time and temperature and assay type
. Osteoporos Int
. 2016 Jul
;27
(7
):2345
–53
.35.
Faul
C
, Amaral
AP
, Oskouei
B
, Hu
MC
, Sloan
A
, Isakova
T
, FGF23 induces left ventricular hypertrophy
. J Clin Invest
. 2011 Nov
;121
(11
):4393
–408
.36.
Grabner
A
, Amaral
AP
, Schramm
K
, Singh
S
, Sloan
A
, Yanucil
C
, Activation of cardiac fibroblast growth factor receptor 4 causes left ventricular hypertrophy
. Cell Metab
. 2015 Dec 1
;22
(6
):1020
–32
.37.
Leifheit-Nestler
M
, Grosse Siemer
R
, Flasbart
K
, Richter
B
, Kirchhoff
F
, Ziegler
WH
, Induction of cardiac FGF23/FGFR4 expression is associated with left ventricular hypertrophy in patients with chronic kidney disease
. Nephrol Dial Transplant
. 2016 Jul
;31
(7
):1088
–99
.38.
Fatah
H
, Benfaed
N
, Chana
RS
, Chunara
MH
, Barratt
J
, Baines
RJ
, Reduced proximal tubular expression of protein endocytic receptors in proteinuria is associated with urinary receptor shedding
. Nephrol Dial Transplant
. 2018 Jun 1
;33
(6
):934
–43
.39.
Taal
MW
, Thurston
V
, McIntyre
NJ
, Fluck
RJ
, McIntyre
CW
. The impact of vitamin D status on the relative increase in fibroblast growth factor 23 and parathyroid hormone in chronic kidney disease
. Kidney Int
. 2014 Aug
;86
(2
):407
–13
. .40.
Calvo
MS
, Moshfegh
AJ
, Tucker
KL
. Assessing the health impact of phosphorus in the food supply: issues and considerations
. Adv Nutr
. 2014 Jan
;5
(1
):104
–13
. .41.
Gutierrez
OM
, Anderson
C
, Isakova
T
, Scialla
J
, Negrea
L
, Anderson
AH
, Low socioeconomic status associates with higher serum phosphate irrespective of race
. J Am Soc Nephrol
. 2010 Nov
;21
(11
):1953
–60
.42.
Yuen
SN
, Kramer
H
, Luke
A
, Bovet
P
, Plange-Rhule
J
, Forrester
T
, Fibroblast growth factor-23 (FGF-23) levels differ across populations by degree of industrialization
. J Clin Endocrinol Metab
. 2016 May
;101
(5
):2246
–53
.43.
Orlandi
PF
, Huang
J
, Fukagawa
M
, Hoy
W
, Jha
V
, Oh
KH
, A collaborative, individual-level analysis compared longitudinal outcomes across the International Network of Chronic Kidney Disease (iNETCKD) cohorts
. Kidney Int
. 2019 Nov
;96
(5
):1217
–33
.44.
Komaba
H
, Fukagawa
M
. FGF23-parathyroid interaction: implications in chronic kidney disease
. Kidney Int
. 2010 Feb
;77
(4
):292
–8
. .45.
Tominaga
Y
. Mechanism of parathyroid tumourigenesis in uraemia
. Nephrol Dial Transplant
. 1999
;14 Suppl 1
:63
–5
. .46.
Mehta
R
, Cai
X
, Lee
J
, Xie
D
, Wang
X
, Scialla
J
, Serial fibroblast growth factor 23 measurements and risk of requirement for kidney replacement therapy: the CRIC (Chronic Renal Insufficiency Cohort) study
. Am J Kidney Dis
. 2020 Jun
;75
(6
):908
–18
.47.
Kendrick
J
, Cheung
AK
, Kaufman
JS
, Greene
T
, Roberts
WL
, Smits
G
, FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis
. J Am Soc Nephrol
. 2011 Oct
;22
(10
):1913
–22
.48.
Pasch
A
, Farese
S
, Graber
S
, Wald
J
, Richtering
W
, Floege
J
, Nanoparticle-based test measures overall propensity for calcification in serum
. J Am Soc Nephrol
. 2012 Oct
;23
(10
):1744
–52
.49.
Budoff
MJ
, Young
R
, Burke
G
, Jeffrey Carr
J
, Detrano
RC
, Folsom
AR
, Ten-year association of coronary artery calcium with atherosclerotic cardiovascular disease (ASCVD) events: the multi-ethnic study of atherosclerosis (MESA)
. Eur Heart J
. 2018 Jul 1
;39
(25
):2401
–8
.50.
Isaka
Y
, Hamano
T
, Fujii
H
, Tsujimoto
Y
, Koiwa
F
, Sakaguchi
Y
, Optimal phosphate control related to coronary artery calcification in dialysis patients
. J Am Soc Nephrol
. 2021 Mar
;32
(3
):723
–35
.51.
Wolf
M
, Koch
TA
, Bregman
DB
. Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women
. J Bone Miner Res
. 2013 Aug
;28
(8
):1793
–803
. .© 2022 S. Karger AG, Basel
2022
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
